First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Tarsus Pharmaceuticals: the setup is constructive — XDEMVY quarterly prescription volume trends (TRx and NRx data from IQVIA) and revenue beat/miss versus consensus
growth - Attracts growth-oriented investors seeking exposure to commercial-stage biotech with blockbuster potential in large underserved…
Rising interest rates negatively impact valuation multiples for pre-profitable biotech companies as investors discount future cash flows…
Watch on earnings: XDEMVY weekly prescription trends from Symphony Health/IQVIA tracking services, Quarterly net revenue per prescription (measuring gross-to-net erosion from rebates/discounts), Prescriber base expansion (total active prescribers and new prescriber adds per quarter).
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $704M to $906M as xdemvy quarterly prescription volume trends (trx and nrx data from iqvia) and revenue beat/miss versus consensus.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.